NASDAQ:WVE - Wave Life Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 529.92 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.27
▼ -0.04 (-3.05%)

This chart shows the closing price for WVE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Wave Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WVE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WVE

Analyst Price Target is $8.00
▲ +529.92% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is $8.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 529.92% upside from the last price of $1.27.

This chart shows the closing price for WVE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Wave Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022HC WainwrightLower Price Target$10.00 ➝ $8.00High
3/4/2022HC WainwrightReiterated RatingBuy$10.00Medium
9/29/2021HC WainwrightReiterated RatingBuy$10.00High
5/19/2021MizuhoBoost Price TargetBuy$7.00 ➝ $8.00Low
3/30/2021Truist FinancialLower Price Target$27.00 ➝ $17.00High
3/30/2021SVB LeerinkLower Price TargetMarket Perform$10.00 ➝ $7.00High
3/30/2021MizuhoLower Price TargetBuy$21.00 ➝ $7.00High
3/30/2021Royal Bank of CanadaLower Price TargetSector Perform$13.00 ➝ $8.00High
3/11/2021MizuhoBoost Price TargetBuy$19.00 ➝ $21.00Medium
3/7/2021Royal Bank of CanadaReiterated RatingHoldHigh
3/7/2021SVB LeerinkReiterated RatingHold$10.00High
12/15/2020HC WainwrightReiterated RatingBuy$20.00Low
11/20/2020MizuhoLower Price TargetBuy$21.00 ➝ $19.00Low
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$13.00High
9/22/2020Truist FinancialBoost Price Target$20.00 ➝ $27.00Low
6/7/2020MizuhoReiterated RatingBuy$21.00High
1/2/2020HC WainwrightLower Price TargetBuy$33.00 ➝ $20.00Low
12/31/2019SunTrust BanksReiterated RatingBuy$20.00Medium
12/31/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$33.00 ➝ $10.00High
12/30/2019MizuhoInitiated CoverageBuy$65.00Low
12/17/2019SunTrust BanksLower Price TargetBuy$39.00 ➝ $27.00High
12/17/2019GuggenheimLower Price TargetBuy$43.00 ➝ $25.00High
12/16/2019MizuhoInitiated CoverageBuy$65.00High
12/16/2019CowenReiterated RatingHoldHigh
11/21/2019MizuhoInitiated CoverageBuy$65.00Medium
11/1/2019GuggenheimInitiated CoverageBuy$43.00High
10/9/2019HC WainwrightSet Price TargetBuy$33.00Low
9/25/2019MizuhoReiterated RatingBuyLow
7/31/2019HC WainwrightReiterated RatingBuyHigh
7/30/2019CowenReiterated RatingHoldHigh
7/22/2019MizuhoReiterated RatingBuy$65.00High
7/15/2019CowenInitiated CoverageMarket Perform ➝ Market PerformMedium
6/29/2019MizuhoSet Price TargetBuy$65.00High
6/28/2019HC WainwrightSet Price TargetBuy$33.00High
5/20/2019SunTrust BanksLower Price TargetBuy$39.00High
5/13/2019HC WainwrightReiterated RatingBuy$33.00Medium
4/17/2019HC WainwrightReiterated RatingBuy ➝ Buy$49.00 ➝ $33.00High
4/16/2019Stifel NicolausDowngradeBuy ➝ HoldHigh
4/15/2019MizuhoReiterated RatingBuy$65.00Low
12/10/2018HC WainwrightSet Price TargetBuy$49.00Medium
12/6/2018MizuhoSet Price TargetBuy$65.00Medium
11/27/2018SVB LeerinkInitiated CoverageOutperform$61.00High
11/12/2018HC WainwrightSet Price TargetBuy$49.00High
11/11/2018SVB LeerinkReiterated RatingOutperformMedium
8/10/2018HC WainwrightSet Price TargetBuy$49.00High
8/9/2018MizuhoSet Price TargetBuy$65.00Medium
8/6/2018Stifel NicolausInitiated CoverageBuy$56.00Low
7/23/2018HC WainwrightReiterated RatingBuy$49.00Low
6/29/2018MizuhoSet Price TargetBuy$65.00High
3/19/2018MizuhoBoost Price TargetBuy ➝ Buy$34.00 ➝ $65.00High
3/13/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$64.00 ➝ $62.00High
3/9/2018SunTrust BanksBoost Price TargetBuy$60.00Low
3/4/2018SVB LeerinkReiterated RatingOutperformHigh
2/21/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$53.00 ➝ $64.00Medium
2/20/2018MizuhoSet Price TargetBuy$34.00Medium
11/15/2017SVB LeerinkReiterated RatingOutperform$42.00 ➝ $53.00N/A
10/21/2017MizuhoSet Price TargetBuy$34.00N/A
8/18/2017MizuhoSet Price TargetBuy$34.00Low
8/10/2017Jefferies Financial GroupReiterated RatingBuy$42.00 ➝ $40.00Low
6/9/2017JMP SecuritiesReiterated RatingOutperform$40.00Low
6/8/2017Jefferies Financial GroupSet Price TargetBuy$42.00Low
(Data available from 5/26/2017 forward)

News Sentiment Rating

-0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
2/25/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/27/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/26/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
5/26/2022

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
Wave Life Sciences logo
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $1.27
Low: $1.25
High: $1.32

50 Day Range

MA: $1.91
Low: $1.23
High: $2.50

52 Week Range

Now: $1.27
Low: $1.16
High: $7.55

Volume

152,419 shs

Average Volume

371,937 shs

Market Capitalization

$77.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Wave Life Sciences?

The following equities research analysts have issued stock ratings on Wave Life Sciences in the last twelve months: HC Wainwright, StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for WVE.

What is the current price target for Wave Life Sciences?

0 Wall Street analysts have set twelve-month price targets for Wave Life Sciences in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 529.9%.
View the latest price targets for WVE.

What is the current consensus analyst rating for Wave Life Sciences?

Wave Life Sciences currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe WVE will outperform the market and that investors should add to their positions of Wave Life Sciences.
View the latest ratings for WVE.

How do I contact Wave Life Sciences' investor relations team?

Wave Life Sciences' physical mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company's listed phone number is (656) 236-3388 and its investor relations email address is [email protected] The official website for Wave Life Sciences is www.wavelifesciences.com. Learn More about contacing Wave Life Sciences investor relations.